TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03924466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68GaNOTA-Anti-HER2 VHH1
Description: All subjects will receive at least one single intravenous injection of the IMP followed by a total body PET/CT prior to receiving standard-of-care therapy.~A second injection of the IMP can be administered before or during standard-of-care treatment, depending on cohort.
Study: NCT01657929

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5-VLP + GLA-AF
Description: H5-VLP antigen and GLA-AF adjuvant. 2 injections at Days 0, and 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5-VLP + GLA-AF
Description: H5-VLP antigen and GLA-AF adjuvant. 2 injections at Days 0, and 21.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5-VLP alone
Description: H5-VLP antigen alone. 2 injections at Days 0, and 21.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5-VLP + Alhydrogel(R)
Description: H5-VLP antigen and Alhydrogel(R) adjuvant. 2 injections at Days 0, and 21.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed H5N1 vaccine
Description: Licensed H5N1 vaccine. 2 injections given on Days 0 and 21.
Study: NCT00079014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03986762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clavulanic Acid
Description: \~10 days of Clavulanic Acid
Study: NCT02633618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Analgecine
Description: Extraction from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurotropin
Description: a natural bio-product obtained from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
Study: NCT05396703

Intervention type: PROCEDURE
Intervention: TOETVA
Description: Completed procedure.
Study: NCT01064245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-dose methacholine challenge test
Description: nebulized liquid inhalation, 0.0625 - 256 mg/mL, doubling doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-dose methacholine challenge test
Description: nebulized liquid inhalation, 0.0625 - 256 mg/mL, doubling doses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mannitol challenge test
Description: inhaled powder, 0 - 635 mg, increments of 5,10, 20 and 40 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mannitol challenge test
Description: inhaled powder, 0 - 635 mg, increments of 5,10, 20 and 40 mg
Study: NCT02225392

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchial thermoplasty
Description: Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty
Description: Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alair system (Boston Scientific, USA)
Description: The alair system consist of a controller and a bastket catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alair system (Boston Scientific, USA)
Description: The alair system consist of a controller and a bastket catheter.
Study: NCT01030367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PETN, ISDN
Description: Oral dosing of organic nitrates PETN 2x 80mg per day ISDN 2x40mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PETN, ISDN
Description: Oral dosing of organic nitrates PETN 2x 80mg per day ISDN 2x40mg per day

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: PETN, ISDN
Description: Oral dosing of organic nitrates PETN 2x 80mg per day ISDN 2x40mg per day
Study: NCT00816413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Each patient will receive up to four IV infusions administered over 30 minutes of donor T cells at increasing cell doses given at intervals.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation (PBSC)
Description: PBSC are infused intravenously either by infusion or IV push on day 0 through a secure intravenous access (i.e. the double-lumen central catheter place pre transplant) according to institutional guidelines.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: 2.0 GY will be administered on day -1. Total-body irradiation (TBI) will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. It is anticipated that TBI will be given on day -1; however, the timing of TBI administration may be altered by factors beyond the control of the Principal Investigator because of the delivery of unrelated donor stem cells.
Study: NCT05210647

Intervention type: DEVICE
Intervention: robotic surgery
Description: by da Vinci Xi
Study: NCT06103097

Intervention type: OTHER
Intervention: No interventions done (obervational)
Description: Observational study
Study: NCT02981095

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thyroidectomy
Description: Thyroidectomy performed by the same surgical and anesthesia team

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Thyroidectomy
Description: Thyroidectomy performed by the same surgical and anesthesia team

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine 0.5%, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: %0.9 sodium chloride solution, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
Study: NCT01870258

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ANN prediction of myocardial infarction

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ANN prediction of myocardial infarction
Study: NCT01146080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Promus Element
Description: Promus Element implanted to treat coronary artery lesions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Promus
Description: Promus stent implanted to treat coronary artery lesions
Study: NCT03192397

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV
Study: NCT03915756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drainage of surgical wound
Description: Introduction of a drain before full fascial closure
Study: NCT03192397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given IV and PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT00731939

Intervention type: DEVICE
Group type: OTHER
Intervention: Inflatable Penile Prosthesis
Description: Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction.
Study: NCT03485118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS006+CHOP
Description: Drug:HS006 HS006 375 mg per square meter (mg/m\^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS006+CHOP
Description: Drug:HS006 HS006 500 mg per square meter (mg/m\^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles. During cycle 1,HS006 also infused on Day 8 and 15.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 1-5 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab+CHOP
Description: Drug:Rituxan Rituxan 375 mg per square metre (mg/m\^2), administered by intravenous (IV) on Day 1 of each 21-day cycle.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle.
Study: NCT04463108

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
Study: NCT01394419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine 150 mg/kg bolus over 15 min after induction of anesthesia, followed by an infusion of 150 mg/kg/day for 24 hrs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Equal volume of normal saline
Study: NCT03482180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KI1106 4g, QD
Description: KI1106 4 Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium 20mg, QD
Description: Atorvastatin Calcium 20mg
Study: NCT00111787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Daily-monotherapy \[1500 milligrams (mg)\] for 14 days, then daily combination therapy (with weekly paclitaxel) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Weekly (80mg/m\^2) combination therapy (with daily Lapatinib) for 12 weeks
Study: NCT03090022

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice
Description: Intra-abdominally Fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single running suture of abdominal fascia
Description: Intra-abdominal suture
Study: NCT04626440

Intervention type: PROCEDURE
Intervention: Diagnostic stage or the Clinical outcome
Description: After enrollment, individual subject will be assigned into one of the four groups according to the medical management received, the diagnostic stage of breast cancer (BC), or the clinical outcome of BC at enrollment.

Intervention type: PROCEDURE
Intervention: Diagnostic stage or the Clinical outcome
Description: After enrollment, individual subject will be assigned into one of the four groups according to the medical management received, the diagnostic stage of breast cancer (BC), or the clinical outcome of BC at enrollment.

Intervention type: PROCEDURE
Intervention: Diagnostic stage or the Clinical outcome
Description: After enrollment, individual subject will be assigned into one of the four groups according to the medical management received, the diagnostic stage of breast cancer (BC), or the clinical outcome of BC at enrollment.
Study: NCT00899951

Intervention type: DRUG
Intervention: fentanyl citrate

Intervention type: OTHER
Intervention: pharmacological study
Study: NCT00382187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted H5N1 influenza vaccine
Description: * MF59 adjuvanted (H5N1) influenza vaccine (Vietnam strain) containing 7.5 mg or 15 mg of H5N1~* non-adjuvanted influenza vaccine containing 15 ug of H5N1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted H5N1 influenza vaccine
Description: * MF59 adjuvanted (H5N1) influenza vaccine (Vietnam strain) containing 7.5 mg or 15 mg of H5N1~* non-adjuvanted influenza vaccine containing 15 ug of H5N1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted H5N1 influenza vaccine
Description: * MF59 adjuvanted (H5N1) influenza vaccine (Vietnam strain) containing 7.5 mg or 15 mg of H5N1~* non-adjuvanted influenza vaccine containing 15 ug of H5N1
Study: NCT03101358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment
Description: One (1) Finger Tip Unit (FTU), or approximately 0.5 g, of SOR007 ointment will be applied topically to a 50 cm2 treatment area.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment
Description: One (1) Finger Tip Unit (FTU), or approximately 0.5 g, of SOR007 ointment will be applied topically to a 50 cm2 treatment area.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment
Description: One (1) Finger Tip Unit (FTU), or approximately 0.5 g, of SOR007 ointment will be applied topically to a 50 cm2 treatment area.
Study: NCT02160613

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open flap debridement
Description: an access flap
Study: NCT01669980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Description: * Subjects ≥ 6 months: IV ceftaroline fosamil 15 mg/kg (or 600 mg if \> 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour)~* Subjects \< 6 months: IV ceftaroline fosamil 10 mg/kg infused over 120 (± 10) minutes q8h (± 1 hour)~Optional Oral Switch:~* PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~* PO clindamycin 13 mg/kg/dose~* PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h
Study: NCT01435746

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: The intervention of this trial is the regime of red blood cell transfusion. The control group will receive red blood cell transfusions according to a conservative regime, whereas the experimental group will receive red blood cell transfusion according to a liberal transfusion regime.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Description: The intervention of this trial is the regime of red blood cell transfusion. The control group will receive red blood cell transfusions according to a conservative regime, whereas the experimental group will receive red blood cell transfusion according to a liberal transfusion regime.
Study: NCT01669980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Ceftriaxone and Vancomycin
Description: * IV ceftriaxone 75 mg/kg/day (up to 4 g/day) divided equally every 12 hours (q12h) (± 2 hours) infused over 30 (± 10) minutes AND~* IV vancomycin 15 mg/kg every 6 hours (q6h) (± 1 hour) infused over at least 60 minutes.~Optional Oral Switch:~* PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~* PO clindamycin 13 mg/kg/dose~* PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h
Study: NCT03147053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jiedu Tongluo granules
Description: Patients in this group were administered the Jiedu Tongluo granules, 3.9mg/bag, 2 times/day for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group were administered the placebo, 3.9mg/bag, 2 times/day for 8 weeks.
Study: NCT01789502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully covered metal stents
Description: Fully covered metal stents were inserted by ERCP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic stents
Description: Plastic stents were inserted by ERCP
Study: NCT01852214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Patients receiving prasugrel will be treated with 60mg loading dose and 10mg maintenance dose
Study: NCT03455764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.
Study: NCT01852214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Patients receiving prasugrel will be treated with 60mg loading dose and 10mg maintenance dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Patients receiving ticagrelor will be treated with a 180mg loading dose and 90mg bid maintenance dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Patients receiving ticagrelor will be treated with a 180mg loading dose and 90mg bid maintenance dose
Study: NCT01856829

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
Study: NCT05136469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEURAL GLIDING
Description: with Sciatic nerve gliding which is done by applying force on the proximal point and releasing the force distally and then reversing the process. This process was achieved for 30 seconds, 6 times on each leg for a total time of 3 minutes (360 seconds).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DYNAMIC STRETCH
Description: The stretch force was applied on the ankle in downward direction which was held for 30 seconds and was repeated 5 times total of 2.5 minutes (150 seconds). Stretch was given on both legs one at a time. Treatment was given for 3 weeks with 2 sessions per week
Study: NCT04434716

Intervention type: DEVICE
Group type: OTHER
Intervention: Feasibility of wearing a Readiband to monitor Sleep and Fatigue
Description: On day one of the study participants will complete a demographic survey. On day one, every seventh day and at the end of the study each participant will complete all the scales; The Minnesota Living with Heart Failure Questionnaire (MLHFQ) and Self-Care of Heart Failure Index will be completed on day one and day 60. At the end of the intervention an Interview will be conducted to assess participants experiences using the Readiband: On a scale of 0-10, how would you rate your digital literacy? 2) Why that number? 3) Tell me about a day using the readiband? 4) Were there any challenges to wearing the band, forgetting to wear it, level of comfort wearing the band? Anything else etc..? 5) How did the digital tools enhance your health? 6) Did the use of digital tools cause you to take a proactive approach rather than a reactive approach to your health? 7) As I use the readiband in a next study, what suggestions do you have for me?
Study: NCT02997176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Daily oral doses of talazoparib 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Daily oral doses of talazoparib 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Daily oral doses of talazoparib 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Daily oral doses of talazoparib 0.5 mg
Study: NCT01927380

Intervention type: OTHER
Intervention: steep trendelenburg position with pneumoperitoneum
Description: ANS activity and baroreflex modulation is assessed at (i) baseline; (ii) after induction of general anesthesia; (iii) after steep trendelenburg position (head down at 25 degrees); (iv) after induction of pneumoperitoneum and (v) after removal of trendelenburg and pneumoperitoneum
Study: NCT02227238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: DTG is supplied as 50 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LPV/RTV
Description: LPV/RTV is supplied as the LPV/RTV oral tablet, which contains 200 mg of LPV and 50 mg of RTV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two NRTIs
Description: Investigators will choose a dual NRTI background regimen for each subject . In consultation with the medical monitor, 3TC may be added as a third NRTI to a dual-NRTI background regimen in subjects with chronic HBV infection and evidence of HIV resistance to 3TC
Study: NCT01856829

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.